Vertex Pharma and partner CRISPR Therapeutics will start a rolling marketing application in the US for their gene-editing drug for sickle cell disease (SCD) and beta thalassaemia later this
In the latest episode of the podcast Dominic Tyer speaks with Nicola Massey, who’s Vertex’s senior country manager in the UK and Ireland. Having joined the biopharmaceutical compan
CRISPR Therapeutics is to receive a hefty $900m payment from Vertex after the companies amended a collaboration to develop, manufacture and market a gene editing therapy for sickle cell dis
Bristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies by market cap into the top 10, according to a new analysis by GlobalDat
The COVID-19 crisis is causing a surge in interest in ‘virtual trials’ where the bulk of the data is collected using digital technology and often from a patient’s own home, a conference hea